Connect with us

Hi, what are you looking for?

AI Research

Nucleai Advances Lung Cancer Immunotherapy Insights with AI-Driven Spatial Analysis

Nucleai’s AI-driven spatial analysis reveals how tumor cell positioning and glucose metabolism can predict immunotherapy success in lung cancer patients.

Nucleai's AI-driven spatial analysis reveals how tumor cell positioning and glucose metabolism can predict immunotherapy success in lung cancer patients.

TEL AVIV, Israel–(BUSINESS WIRE)–Nucleai, an AI-powered multimodal spatial biology company, has contributed to a groundbreaking study published in Nature Communications, which investigates how the positioning of tumor cells and their glucose utilization can predict the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC). The research was conducted in collaboration with The University of Queensland and Yale School of Medicine, highlighting the critical role of tumor microenvironments in treatment responses.

The study employed multiplex immunofluorescence (mIF) and advanced computational techniques to analyze tumor tissues at a single-cell resolution. By focusing on the spatial arrangement and metabolic characteristics of different cell populations within the tumor microenvironment, researchers were able to discern distinct patterns that correlate with patient responses to immunotherapy.

Nucleai’s AI-driven mIF analysis pipeline played a significant role in the study, allowing for the precise identification and classification of tumor and immune cell populations on a large scale. This technological contribution provided a robust foundation for the subsequent spatial and metabolic analyses conducted by the academic teams involved.

“Understanding response to lung cancer treatment requires insight into the different cell states and cell-cell interactions within the tumor, not just which cells and markers are present,” said Ettai Markovits, Director of Biomedical Research at Nucleai. “This study highlights the importance of spatial context in cancer biology, and we are pleased to have supported this work by enabling robust, AI-based spatial analysis applied to multiplex imaging data.”

Immunotherapy has significantly changed the treatment paradigm for lung cancer; however, a limited number of patients achieve sustained benefits. The findings from this study indicate that specific spatially defined metabolic features within tumors may help explain the variability in treatment responses, underscoring the need for more complex approaches to characterizing tumor biology beyond traditional single-marker assessments.

This research aligns with Nucleai’s mission, leveraging its multimodal spatial AI platform designed to facilitate scalable and rapid spatial profiling across extensive research cohorts. The platform transforms complex multiplex imaging data into structured, quantitative spatial insights, aiding collaborative efforts aimed at advancing precision oncology research.

“This study demonstrates the power of multiplex imaging data to shed light on nuanced spatial interactions linked to treatment response to immunotherapy,” stated Associate Professor Arutha Kulasinghe from UQ’s Frazer Institute. “However, translating this spatial complexity into clinical insights requires sophisticated computational analysis. Nucleai’s contributions helped connect high-dimensional spatial imaging with clinical outcomes more efficiently.”

The collaborative research involved various institutions, including The University of Queensland’s Frazer Institute, Yale School of Medicine, Wesley Research Institute, Quanterix, and Nucleai, and is published in Nature Communications.

About Nucleai

Nucleai is at the forefront of AI-powered multimodal spatial biology, turning tissue imaging into actionable insights for drug development and diagnostics. The company’s multimodal spatial operating system integrates high-plex spatial proteomics, histopathology, and clinical data to identify predictive spatial biomarkers and drive the development of next-generation precision medicine products. Nucleai collaborates with prominent pharmaceutical, diagnostic, and academic institutions worldwide. For more information, visit nucleai.ai.

Media Contact
Patrick Schmidt
[email protected]

See also
Staff
Written By

The AiPressa Staff team brings you comprehensive coverage of the artificial intelligence industry, including breaking news, research developments, business trends, and policy updates. Our mission is to keep you informed about the rapidly evolving world of AI technology.

You May Also Like

Top Stories

Tensions in the Middle East lead to XRP's price hovering at $1.42, while analysts forecast potential volatility and recovery targets up to $1.80 amid...

AI Generative

Synthetic media's rise amid U.S.-Israel-Iran tensions fuels disinformation, complicating conflict narratives and undermining public trust in media accuracy

AI Technology

Nvidia, Digital Realty, and Credo Technology are positioned to capitalize on a $700 billion AI infrastructure boom as major tech firms ramp up investments.

AI Technology

US and Israeli forces executed 1,000 AI-targeted strikes in 24 hours, doubling Iraq War's scale, raising urgent accountability and ethical concerns.

AI Regulation

Security flaws in Anthropic's Claude Code expose a bypass for safety protocols, enabling unauthorized curl command execution through prompt injection attacks.

Top Stories

Artlist integrates Google’s Lyria 3 Pro, enabling creators to generate original, studio-quality tracks up to three minutes long, enhancing its AI Toolkit for 50...

AI Generative

Netanyahu's video response to death rumors sparks AI-generated misinformation debate, highlighting the urgent need for content verification amid escalating digital warfare.

AI Marketing

Dabur distances itself from a controversial AI-generated Hajmola ad that sparked debate over marketing ethics amid ongoing LPG supply issues in India.

© 2025 AIPressa · Part of Buzzora Media · All rights reserved. This website provides general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information presented. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult appropriate experts when needed. We are not responsible for any loss or inconvenience resulting from the use of information on this site. Some images used on this website are generated with artificial intelligence and are illustrative in nature. They may not accurately represent the products, people, or events described in the articles.